EUVIMEDEUVIMED felfedezése
Open access

Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma

Zheng Shao, YongLi Situ, Bairu Lai, Ying Xu, Jv Chen, Li Deng, QinYing Xu, Meng Liang, Zhu Liang, ZhanQiang Xie

Journal of Cancer · 2026-05-29 · 17 (6) · 1134-1154

DOI: 10.7150/jca.134792 ↗

At a glance

Journal article in Journal of Cancer, published on 2026-05-29. Written by Zheng Shao and 9 co-authors. Institution: School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong, 524023, China. The full text is freely available in PubMed Central.

AbsztraktSubjectsBibliográfiai adatokCiteRelated studies

Abstract (original language)

Nincs elérhető absztrakt.

Subjects

Author keywords

lung adenocarcinomam6A modificationprognostic modeltreatment response predictiontumor immune landscape

Authors and institutions

  • School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong, 524023, China.
  • School of Medical Technology, Guangdong Medical University, Dongguan, Guangdong, 523808, China.
  • Department of Pharmacy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524023, China.
  • Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524023, China.

Cite

APA

Shao, Z., Situ, Y., Lai, B., Xu, Y., Chen, J., Deng, L., Xu, Q., Liang, M., Liang, Z., & Xie, Z. (2026). Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma. Journal of Cancer, 17(6), 1134-1154. https://doi.org/10.7150/jca.134792

Vancouver

Shao Z, Situ Y, Lai B, Xu Y, Chen J, Deng L, et al. Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma. Journal of Cancer. 2026;17(6):1134-1154. doi:10.7150/jca.134792

BibTeX
@article{Shao2026,
  author = {Shao, Zheng and Situ, YongLi and Lai, Bairu and Xu, Ying and Chen, Jv and Deng, Li and Xu, QinYing and Liang, Meng and Liang, Zhu and Xie, ZhanQiang},
  title = {Development and Validation of an m6A-Derived Prognostic Signature in Lung Adenocarcinoma},
  journal = {Journal of Cancer},
  year = {2026},
  volume = {17},
  number = {6},
  pages = {1134--1154},
  doi = {10.7150/jca.134792}
}
Start for free →